Hydroxycarbamide in Anemia, Sickle Cell: NCT06464458 Clinical Landscape Report 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Executive view

NCT06464458 evaluates Hydroxycarbamide in Anemia, Sickle Cell. The disclosed sponsor is Les Hopitaux Universitaires de Strasbourg, the design is Interventional, and the geographic footprint is France. The first listed primary endpoint is Comparison of the time to obtained MTD in 2 groups of sickle cell patients on hydroxyurea with different treatment follow-up methodology: MTD follow up or therapeutic pharmacological monitoring, assessed over Theoretical start date: January 2023 Duration of inclusion period: 30 months Duration of participation of each subject: 16 months Total study duration: 46 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06464458 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Anemia, Sickle Cell landscape. Drug & Asset MCP drug_fetch was queried for Hydroxycarbamide, while Company & Deal Intelligence MCP organization_fetch was queried for Les Hopitaux Universitaires de Strasbourg.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06464458 is a Not Applicable, unknown status study with 30 planned participants. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment.

The primary endpoint is “Comparison of the time to obtained MTD in 2 groups of sickle cell patients on hydroxyurea with different treatment follow-up methodology: MTD follow up or therapeutic pharmacological monitoring” over “Theoretical start date: January 2023 Duration of inclusion period: 30 months Duration of participation of each subject: 16 months Total study duration: 46 months.” The retrieved endpoint description is: \- Arm A (Control): The dosage adjustment is quarterly from M3 onwards and will be made on hematological (WBC) tolerance. The increase of the dosage in HU will be 5 mg/kg every 3 months (or 2.5 mg/kg in case of renal insufficiency with ClCr ≤ 60 ml /min) until MTD is achieved and within a limit of 35 mg/kg/day (max 2500mg). \- Arm B (Experimental): Dose adjustment will be done at the M3 visit based on the results of the Pharmacokinetic analysis (AUC) performed on the day of the first HU intake after inclusion. At the quarterly visits V1 (3 months) to V4 (12 months), a HU assay at time T = 2H associated with moni….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 30 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Anemia, Sickle Cell. These records do not establish direct evidence for NCT06464458 unless the registration number matches.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Hydroxycarbamide is indexed as Small molecule drug with RNRs biology and a global stage of Approved. The asset profile lists Bristol Myers Squibb Co. as an originator or developer.

Les Hopitaux Universitaires de Strasbourg is indexed in France with the website http://www.chru-strasbourg.fr. University Hospital Strasbourg provides medicine, surgery, and gynecology-obstetrics treatment services. The record lists an unreported number of development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

1. Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
2. Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
3. Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
4. Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
5. Sequencing white space. Clarify whether Hydroxycarbamide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06464458
Protocol source: https://clinicaltrials.gov/study/NCT06464458
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.

Hydroxycarbamide in Anemia, Sickle Cell is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Comparison of the time to obtained MTD in 2 groups of sickle cell patients on hydroxyurea with different treatment follow-up methodology: MTD follow up or therapeutic pharmacological monitoring and 2025-08-07 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP